Cugene Inc.
↗Waltham, USA
Cugene Inc. is a clinical-stage biotechnology company focused on the discovery and development of next-generation precision immunology and oncology medicines. The company leverages advanced bioengineering to create therapies that harness specific immune cells, such as regulatory T cells (Tregs) and tumor-infiltrating lymphocytes (TILs), to treat autoimmune diseases and cancer.
Cugene's proprietary platforms include TILKine™ (TIL-targeting bispecifics) and VitoKine™ (bioactivatable, masked cytokines), designed to improve receptor selectivity, enhance half-life, and limit systemic toxicity. Their lead asset, CUG252, is a potential best-in-class Treg-selective IL-2 mutein currently being evaluated in Phase 1 clinical trials for the treatment of autoimmune and inflammatory conditions.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Oncology & Immunology biotech
SIZE & FINANCIALS
Employees:1-50
Revenue:$3M-$5M (Estimated)
Founded:2016
Ownership:private
Status:operating
FUNDING
Stage:Series B (Estimated)
Total Raised:$48.5M+
Investors:Summer Capital (China), Ally Bridge Group, AbbVie (Strategic Partner)
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1b
Modalities:mAb, Fusion protein, Cytokine, Bispecific, IL-2 Mutein
Active Trials:1
Trial Phases:Phase 1: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:AbbVie: Exclusive worldwide license option agreement for CUG252 and other novel IL-2 muteins signed in May 2022.
COMPETITION
Position:Emerging
Competitors:Nektar Therapeutics (NKTR-358), Amgen (Efavaleukin alfa), Roche (RG6234), Eli Lilly (LY3471851), Sonoma Biotherapeutics, Egle Therapeutics
LEADERSHIP
Key Executives:
Luke Li, M.D. - CEO & Founder
Jianguo Xia - EVP of Research & Development
Lin Rao - Head of Protein Sciences
Scientific Founders:Luke Li, M.D.
Board Members:Luke Li, Rizwan Romee (SAB Member)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Cugene Inc.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.